A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Trial Profile

A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Aripiprazole lauroxil (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics; Registrational
  • Sponsors Alkermes plc
  • Most Recent Events

    • 06 Jun 2017 According to an Alkermes media release, that the US FDA has approved two-month ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
    • 20 Mar 2017 According to an Alkermes media release, a supplemental New Drug Application (sNDA) for the two-month dosing option of ARISTADA is currently under review with the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) action date of June 5, 2017.
    • 20 Mar 2017 According to an Alkermes media release, data from this study will be presented at the 16th International Congress on Schizophrenia Research (ICOSR)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top